PMID- 38000309
OWN - NLM
STAT- MEDLINE
DCOM- 20231204
LR  - 20231217
IS  - 1873-4235 (Electronic)
IS  - 0956-5663 (Linking)
VI  - 245
DP  - 2024 Feb 1
TI  - Therapeutic drug monitoring mediated by the cooperative chemical and 
      electromagnetic effects of Ti(3)C(2)T(X) modified with Ag nanocubes.
PG  - 115844
LID - S0956-5663(23)00786-8 [pii]
LID - 10.1016/j.bios.2023.115844 [doi]
AB  - It is pivotal for the credible utilization of surface-enhanced Raman scattering 
      (SERS) technique in clinical drug monitoring to exploit versatile substrates with 
      dependable quantitative detection and robust recognition abilities. Herein, a 
      commendable electromagnetic-chemical dual-enhancement SERS substrate dependent on 
      Ti(3)C(2)T(X) and Ag nanocubes (Ag NCs) was fabricated for the precise 
      quantification of ritonavir and ibrutinib in serum. Specifically, it was revealed 
      that numerous electromagnetic "hotspots" emerged nearby the extremely tiny 
      nanogaps among the intimately clustered Ag NCs, which also acted as optimal 
      channels to facilitate effective photo-induced charge transfer (PICT) between the 
      two-dimensional Ti(3)C(2)T(X) matrix and target molecules. The cooperation 
      between electromagnetic and chemical effects yielded a satisfactory enhancement 
      factor (EF) of 4.77 x 10(7) for the composite substrate. Benefiting from the 
      remarkable sensitivity of the Ti(3)C(2)T(X)/Ag NCs composite substrate, the low 
      limit of detection (LOD) at 10(-6) mg/mL was successfully attained, along with 
      exceptional recoveries of exceeding 90% for ritonavir and ibrutinib in serum. 
      Considering its reliability and simplicity, our strategy holds immense promise 
      for its utilization in efficient monitoring and identification of clinical blood 
      drug concentration.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Xue, Danni
AU  - Xue D
AD  - School of Physical Science and Technology, Ningbo University, Ningbo, 315211, 
      Zhejiang, PR China.
FAU - Dai, Xing
AU  - Dai X
AD  - School of Physical Science and Technology, Ningbo University, Ningbo, 315211, 
      Zhejiang, PR China.
FAU - Zhao, Jialong
AU  - Zhao J
AD  - School of Physical Science and Technology, Ningbo University, Ningbo, 315211, 
      Zhejiang, PR China.
FAU - Zhang, Jiayao
AU  - Zhang J
AD  - School of Physical Science and Technology, Ningbo University, Ningbo, 315211, 
      Zhejiang, PR China.
FAU - Liu, Huan
AU  - Liu H
AD  - School of Physical Science and Technology, Ningbo University, Ningbo, 315211, 
      Zhejiang, PR China.
FAU - Liu, Kui
AU  - Liu K
AD  - Ningbo Institute of Oceanography, Ningbo, 315800, Zhejiang, PR China.
FAU - Xu, Tao
AU  - Xu T
AD  - Department of Pharmacy, The First Affiliated Hospital of Ningbo University, 
      Ningbo University, Ningbo, 315010, Zhejiang, PR China.
FAU - Gu, Chenjie
AU  - Gu C
AD  - School of Physical Science and Technology, Ningbo University, Ningbo, 315211, 
      Zhejiang, PR China; Ningbo Institute of Oceanography, Ningbo, 315800, Zhejiang, 
      PR China.
FAU - Zhou, Xingfei
AU  - Zhou X
AD  - School of Physical Science and Technology, Ningbo University, Ningbo, 315211, 
      Zhejiang, PR China. Electronic address: zhouxingfei@nbu.edu.cn.
FAU - Jiang, Tao
AU  - Jiang T
AD  - School of Physical Science and Technology, Ningbo University, Ningbo, 315211, 
      Zhejiang, PR China. Electronic address: jiangtao@nbu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20231121
PL  - England
TA  - Biosens Bioelectron
JT  - Biosensors & bioelectronics
JID - 9001289
RN  - O3J8G9O825 (Ritonavir)
RN  - 3M4G523W1G (Silver)
RN  - D1JT611TNE (Titanium)
SB  - IM
MH  - *Drug Monitoring
MH  - *Biosensing Techniques
MH  - Reproducibility of Results
MH  - Ritonavir
MH  - Silver/chemistry
MH  - Titanium
MH  - Electromagnetic Phenomena
MH  - Spectrum Analysis, Raman/methods
OTO - NOTNLM
OT  - Drug monitoring
OT  - Electromagnetic-chemical dual-enhancement
OT  - Ritonavir and ibrutinib
OT  - SERS
OT  - Ti(3)C(2)T(X)
COIS- Declaration of competing interest The authors declare no competing financial 
      interest.
EDAT- 2023/11/25 07:43
MHDA- 2023/12/04 12:42
CRDT- 2023/11/24 18:11
PHST- 2023/07/04 00:00 [received]
PHST- 2023/09/19 00:00 [revised]
PHST- 2023/11/14 00:00 [accepted]
PHST- 2023/12/04 12:42 [medline]
PHST- 2023/11/25 07:43 [pubmed]
PHST- 2023/11/24 18:11 [entrez]
AID - S0956-5663(23)00786-8 [pii]
AID - 10.1016/j.bios.2023.115844 [doi]
PST - ppublish
SO  - Biosens Bioelectron. 2024 Feb 1;245:115844. doi: 10.1016/j.bios.2023.115844. Epub 
      2023 Nov 21.